Kowa's pharmaceutical business is global, with offices in the United States, Europe and Asia. With a commitment to ground-breaking research, development and marketing, we ensure steady supply of products with quality and reliability to help people around the world enjoy better health.
Livalo® is a prescription drug for the treatment of dyslipidemia developed in Japan by Kowa and with its proven efficacy it has grown into our global product currently marketed in the United States and Asia.
Further launches are expected in Europe and other regions in the near future.

USA

Kowa Pharmaceuticals America, Inc.

Sales and marketing

Kowa Research Institute, Inc.

Research and development

Center for Interdisciplinary Cardiovascular Sciences

Research

Europe

Kowa Pharmaceutical Europe AG

Administration center, Research and development

Kowa Pharmaceutical Europe Co. Ltd.

Sales and marketing

Asia

Kowa Pharmaceutical Asia Pte. Ltd.

Administration center, Research and development

Kowa Pharmaceuticals (China) Co., Ltd.

Sales and marketing, Manufacture

Kowa Korea Company, Ltd.

Sales and marketing

Kowa Taiwan Tsusho Co., Ltd.

Sales and marketing

Kowa (Thailand) Co., Ltd.

Sales and marketing